CELC
Celcuity Inc
NASDAQ · Biotechnology
$106.75
+2.47 (+2.37%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| EPS | — | — | — |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| Rev Growth | +6.2% | -3.6% | +12.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.19B | 2.35B | 2.55B |
| Total Equity | 1.97B | 2.12B | 1.91B |
| D/E Ratio | 1.11 | 1.11 | 1.34 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |